In a phase I study to look at the safety and tolerability of a new drug called sapanisertib, sapanisertib was well-tolerated and showed some anti-tumour activity in patients with renal cell carcinoma (RCC) and endometrial cancer.
Sapanisertib is an oral, highly selective inhibitor of the mTORC1/mTORC2 receptors in advanced solid tumours. In the study, 82 RCC or endometrial cancer patients were treated with various dosing regimens to find the maximum tolerated dose and to look for side effects. Common side effects included high blood sugar levels (hyperglycaemia), skin rash, weakness or lack of energy, and a sore mouth.
One patient with RCC had a complete response and nine patients had partial responses (7 RCC patients). Sapanisertib had tolerable side effects with preliminary anti-tumour activity in patients with RCC and endometrial cancer.